Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 76420-908

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 76420-908). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)
A Kaplan-Meier plot showing the estimated probability of achieving an initial headache response within 2 hours post-dose for Rizatriptan Benzoate tablets 5 mg and 10 mg compared to placebo, based on pooled data from 4 placebo-controlled outpatient studies. The plot indicates increasing response probabilities over time for both dosages, with higher probabilities for the 10 mg dose.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In P (Rizatriptan Fig2)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In P (Rizatriptan Fig2)
A Kaplan-Meier plot showing the estimated probability over 24 hours of patients taking a second dose of Rizatriptan Benzoate tablets (5 mg and 10 mg) or placebo for migraines. The y-axis represents the estimated probability of medication rescue, and the x-axis represents hours post-dose. Three curves compare placebo, 5 mg, and 10 mg Rizatriptan Benzoate tablets.*
FDA Label Image

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)
A Kaplan-Meier plot showing the estimated probability of achieving an initial headache response within 2 hours after dosing with Rizatriptan Benzoate orally disintegrating tablets. The graph compares placebo, 5 mg, and 10 mg tablet groups over time up to 2 hours post-dose, illustrating higher response probabilities with increasing dosage.*
FDA Label Image

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose O (Rizatriptan Fig4)

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose O (Rizatriptan Fig4)
A Kaplan-Meier plot showing the estimated probability over 24 hours of patients taking a second dose of Rizatriptan Benzoate orally disintegrating tablets at 5 mg and 10 mg doses, placebo, or other medication for migraines. The x-axis represents hours post-dose, and the y-axis represents estimated probability of remediation or rescue.*
FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)
A line graph showing the observed percentage of patients reporting no headache pain up to 2 hours after dosing in Study 7. It compares Rizatriptan Benzoate orally disintegrating tablets with placebo over time intervals from 0.5 to 2 hours post-dose, with Rizatriptan showing higher percentages at each time point.*
FDA Label Image

5 mg (Rizatriptan Fig6)

5 mg (Rizatriptan Fig6)
Label for Rizatriptan Benzoate Orally Disintegrating Tablets USP 5 mg by Enovachem Pharmaceuticals. The label includes the NDC 76420-908-18, quantity of 18 tablets, distributor Rising Health, LLC, and handling instructions. It warns against dispensing without prescription and includes storage directions.*
FDA Label Image

10 mg (Rizatriptan Fig7)

10 mg (Rizatriptan Fig7)
Packaging label for Rizatriptan Benzoate Orally Disintegrating Tablets, USP 10 mg, distributed by Rising Health, LLC and relabeled by Envochem Pharmaceuticals. The label indicates a quantity of 18 tablets in the package, with information on drug status (prescription only), storage instructions, and batch and lot details. The label includes a barcode and QR code.*
FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical Structure (Rizatriptan Str)
Chemical structure diagram showing the molecular composition of Rizatriptan Benzoate, the active ingredient in the product.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.